Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 659-665

  Olas, Beata ^a   Wachowicz, Barbara ^a   Majsterek, Ireneusz ^a   Blasiak, Janusz ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Blood platelets; Cisplatin; Comet assay; Isoprostanes; Lymphocytes; Oxidative stress; Resveratrol

Indexed keywords

8 EPIPROSTAGLANDIN F2; 8 ISOPROSTAGLANDIN F2 ALPHA; CELL DNA; CELL PROTEIN; CISPLATIN; CISPLATIN DERIVATIVE; LIPID; PLATINUM DERIVATIVE; RESVERATROL; SELENIUM CISPLATIN CONJUGATE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; GRAPE; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LYMPHOCYTE; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; WINE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOOD; BLOOD PLATELETS; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; COMET ASSAY; DINOPROST; DNA DAMAGE; HUMANS; LIPID PEROXIDATION; LYMPHOCYTES; MALE; OXIDATIVE STRESS; OXIDOREDUCTASES; PLASMA; PLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES; SELENIUM COMPOUNDS; STILBENES;

EID: 20844431536     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00011     Document Type: Article

References (50)

1. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother 2002; 56:84-87.
2. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 2003; 523-524:145-150.
3. Hakimuddin F, Paliyath G, Meckling K. Selective cytotoxicity of a red grape wine flavonoid fraction against MCF-7 cells. Breast Cancer Res Treat 2004; 85:65-79.
4. Olas B, Żbikowska HM, Wachowicz B, Krajewski T, Buczyn̄ski A, Magnuszewska A. Inhibitory effect of resveratrol on free radical generation in blood platelets. Acta Biochim Polon 1999; 46:961-966.
5. Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000; 59:865-870.
6. Żbikowska HM, Olas B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol 2000; 3:513-520.
7. Olas B, Wachowicz B, Saluk-Juszczak J, Zielinski T, Kaca W, Buczyn̄ski A. Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets. Cell Biol Toxicol 2001; 17:117-125.
8. Bertelli AA, Giovannini L, Giannessi DZ, Migliori M, Bernini W, Fregoni M, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995; 17:1-3.
9. Bertelli AA, Giovannini L, Bernini W, Migliori M, Fregoni M, Baveresco L, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996; 22: 61-63.
10. Żbikowska HM, Olas B, Wachowicz B, Krajewski T. Response of blood platelets to resveratrol. Platelets 1999; 10:247-252.
11. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CV, Beecher CHWW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-219.
12. Lin JK, Tsai SH. Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc Natl Sci Council Rep China 1999; 23:99-106.
13. Daniel O, Meier MS, Schlatter J, Schlahter J, Frischhnecht P. Selected phenolic compounds in cultivated plants: ecologic functions, health implications, and modulation by pesticides. Environ Health Perspect 1999; 17:109-114.
14. Olas B, Wachowicz B, Bald E, Glowacki R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J Physiol Pharmacol 2004; 2:467-476.
15. Olas B, Wachowicz B. Resveratrol reduces oxidative stress induced by platinum compounds in blood platelets. Gen Physiol Biophys 2004; 23: 1-12.
16. Keppler BK. Metal complexes in cancer chemotherapy. General remarks. In: Keppler BK (editor): Metal Complexes in Cancer Chemotherapy. Weinheim: VCH; 1993, pp. 1-8.
17. Wachowicz B, Kustroń J. Effect of cisplatin on lipid peroxidation in pig blood platelets. Cytobios 1992; 70:41-47.
18. Wachowicz B. Inhibitory effect of cisplatin on the enzymatic peroxidation of platelet endogenous arachidonate. Cytobios 1993; 75:157-162.
19. Wachowicz B, Szwarocka A. Response of pig blood platelets to cisplatin and sodium selenite: lipid peroxidation and oxygen radical generation. Biomed Lett 1994; 49:147-152.
20. Wachowicz B, Olas B. Changes of platelet cytoskeleton induced by cisplatin in the relation to platelet activation. Biomed Lett 1995; 52: 181-190.
21. Olas B, Wachowicz B. Inhibitory effects of cisplatin and its conjugate with glutathione on blood platelet activation. Platelets 1998; 9:69-72.
22. Olas B, Wachowicz B. Modulation of cisplatin toxicity in blood platelets by glutathione depletion. Anticancer Drugs 1998; 9:473-478.
23. Olas B, Wachowicz B, Buczynski A. Adhesion of blood platelets to collagen and fibrinogen after treatment with cisplatin and its complex with glutathione. Cytobios 2000; 102:75-84.
24. 3) in blood platelets. Gen Physiol Biophys 1997; 16:263-272.
25. 3)) on oxidative stress in blood platelets measured by chemiluminescence method. J Physiol Pharmacol 1999; 50:299-308.
26. Blasiak J, Kowalik J, Malecka-Panas E, Drzewoski J, Wojewodzka M. DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Treatogen Carcinogen Mutagen 2000; 20:119-131.
27. Walkowiak B, Michalak E, Koziolkiewicz W, Cierniewski CS. Rapid photometric method for estimation of platelet count in blood plasma or platelet suspension. Thromb Res 1989; 56:763-766.
28. Wroblewski F, La Due J. Lactic dehydrogeanse activity in blood. Proc Soc Exp Biol Med 1955; 210:210-215.
29. Paglia DE, Valentine WN. Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70:158-169.
30. Hopkins J, Tudhope GE. Glutathione peroxidase in human red cells in health and disease. Br J Haematol 1973; 25:563-575.
31. Bartosz G. Druga twarz tlenu. Warsaw: PWN; 1995.
32. Singh NP, McCoy T, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175:184-192.
33. Collins AR, Duthie SJ, Dobson VL. Direct enzymatic detection of endogenous base damage in human lymphocyte DNA. Carcinogenesis 1993; 14:1733-1735.
34. Evans MD, Podmore ID, Daly GJ, Perrett D, Lunec J, Herbert KE. Detection of purine lesions in cellular DNA using single cell gel electrophoresis with Fpg protein. Biochem Soc Trans 1995; 23:434S.
35. Klaude M, Eriksson S, Nygren J, Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat Res 1996; 363:89-96.
36. Blasiak J, Kowalik J. A comparison of the in vitro genotoxicity of tri- and hexavalent chromium. Mutat Res 2000; 469:135-145.
37. Yen GC, Duh PD, Lin CW. Effects of resveratrol and 4-hexylresorcnol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Rad Res 2003; 37:509-514.
38. Olas B, Wachowicz B. Cisplatin-induced changes of biological activity of blood platelets; thiol-related mechanisms. Anticancer Drugs 1996; 7: 476-482.
39. Olas B, Żbikowska HM. Changes of glutathione S-transferase (GST) activity in blood platelets induced by cisplatin. Biomed Lett 1999; 59:93-99.
40. 2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87:9383-9387.
41. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 2000; 25:1357-1364.
42. Souviget C, Cracowski JL, Stanke-Labesque F, Bessard G. Are isoprostanes a clinical marker for antioxidant drug investigation. Fund Clin Pharmacol 2000; 14:1-10.
43. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23:1-4.
44. Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. The isoprostanes: a perspective. Prostaglandins 1997; 54: 823-851.
45. Taber DF, Morrow JD, Roberts II JL. A nomenclature system for the isoprostanes. Prostaglandins 1997; 53:63-67.
46. 2-isoprostane concentrations in humans. Free Rad Biol Med 2004; 37:411-421.
47. 2α. Prostagland Leukotr Essential Fatty Acids 2000; 62:209-216.
48. Blasiak J, Kowalik J. Protective action of vitamin C against DNA damage induced by selenium-cisplatin conjugate. Acta Biochim Pol 2001; 1: 233-240.
49. Brito O, Almeida LM, Dinis TCP. The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Rad Res 2002; 36:621-631.
50. van Acker FAA, Hulshof JW, Haenen GRMM, Menge WMPB, van der Vijgh WJF, Bast A. New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Rad Biol Med 2001; 31:31-37.